Full-Time

Quality Engineer 2

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Compensation Overview

$65.4k - $96.4k/yr

Mid, Senior

Company Historically Provides H1B Sponsorship

Austin, TX, USA + 1 more

More locations: San Carlos, CA, USA

Hybrid with 25-50% onsite preference; San Carlos, CA preferred; Austin, TX considered.

Category
QA & Testing
Quality Assurance
Requirements
  • Must have clinical laboratory experience in a CAP/CLIA environment
  • Position requirements are a B.S. or equivalent in biology, chemistry, engineering or related field
  • At least 4 years of experience in medical diagnostic, CLIA laboratory, or Life Sciences industry; 2 years experience working in a Quality role preferred
  • Audit experience – internal audits, third party audits and/or regulatory audits
  • American Society of Quality certifications (CQE) preferred
Responsibilities
  • Support internal and external audits (CLIA/CAP, ISO 13485, customer)
  • Support CAPA, Deviation, Change Requests and Nonconformance investigation and reporting
  • Write/revise procedures and forms
  • Support Quality systems compliance to CLIA, FDA QSR, ISO 13485, and HIPAA
  • Participate in the management of Approved Suppliers
  • Follow established company standard operating procedures and good documentation practices
  • Support post-market product improvement
  • Support the development of new products
  • Other duties as assigned
Desired Qualifications
  • Hands on experience with DNA Isolation and Purification, PCR, Cell Culture, Sequencing, Bioinformatics etc.
  • Demonstrated good judgment, excellent attention to detail, excellent written, verbal communication and interpersonal skills are desired with the ability to be flexible and collaborate on multiple projects

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera also offers tests for family planning and prenatal screening, including the Panorama NIPT, which has conducted over 2 million tests. The company generates revenue through testing kits and services, often reimbursed by insurance, and provides genetic counseling for personalized patient support.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption in genetic testing enhances Natera's prenatal and cancer diagnostics.
  • Remote healthcare trends expand the market for Natera's at-home genetic testing kits.
  • Advancements in liquid biopsy technologies benefit Natera's market reach and accessibility.

What critics are saying

  • Increased competition from companies like Lantheus Holdings may impact Natera's market share.
  • The sale of company stock by Natera's CFO might indicate potential internal concerns.
  • Adoption challenges for the Donor Quantity Score in Prospera Heart could affect its success.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for prenatal and cancer diagnostics.
  • The company offers unique tests like Signatera and Prospera Heart with Donor Quantity Score.
  • Natera provides remote genetic counseling, enhancing accessibility for patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

5%
Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).

TXBN
Mar 25th, 2025
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.

Simply Wall St
Mar 13th, 2025
Natera (NasdaqGS:NTRA) Welcomes Former National Cancer Institute Director Back to Board

Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.

Investing.com
Mar 10th, 2025
Natera launches HEROES trial for breast cancer treatment

Natera launches HEROES trial for breast cancer treatment.

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.